Skeletal muscle relaxant drug-drug-drug interactions and unintentional traumatic injury: Screening to detect three-way drug interaction signals.

Cheng Chen^1,2, Sean Hennessy^1,2,3,4, Colleen M Brensinger^1,2, Ghadeer K Dawwas^1,2,3, Emily K Acton^1,2,5, Warren B Bilker^1,6, Sophie P Chung⁷, Sascha Dublin^8,9, John R Horn¹⁰, Todd A Miano^1,2, Thanh Phuong Pham Nguyen^1,5,11, Samantha E Soprano^1,2, Charles E Leonard^1,2,3

¹Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States.

²Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

³Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States.

⁴Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

⁵Translational Center of Excellence for Neuroepidemiology and Neurology Outcomes Research, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

⁶Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

⁷AthenaHealth, Inc, Watertown, MA, United States.

⁸Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States.

⁹Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, United States.

¹⁰Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, United States.

¹¹Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.

PubMed PMC DOI PDF

Abstract

AIM: The aim of this study was to identify skeletal muscle relaxant (SMR) drug-drug-drug interaction (3DI) signals associated with increased rates of unintentional traumatic injury. METHODS: We conducted automated high-throughput pharmacoepidemiologic screening of 2000-2019 healthcare data for members of United States commercial and Medicare Advantage health plans. We performed a self-controlled…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

athenahealth
affiliation

NIH Funding

Grant #11249147
Drug interactions involving psychoactive drugs
UNIVERSITY OF PENNSYLVANIA
$526,888 (FY2026)
Grant #10421347
Enhancing the Utility of the Trend-in-Trend Research Design
UNIVERSITY OF PENNSYLVANIA
$564,584 (FY2022)

Other Funding

NIDA NIH HHS(R01 DA048001)
United States
NIA NIH HHS(R01 AG025152)
United States
NIA NIH HHS(R01 AG060975)
United States
NIA NIH HHS(R01 AG064589)
United States

MeSH Terms

Aged0Alprazolam*Diclofenac0Drug Interactions0Gabapentin0Humans0Medicare0Neuromuscular Agents*Omeprazole0United States0

Keywords

drug interactionsinjurymuscle relaxantspharmacoepidemiologypopulation healthself-controlled case series

Article Info

PMID: 35562168
PMCID: PMC9560998
DOI: 10.1111/bcp.15395
Received: February 23, 2022
Accepted: May 5, 2022

How to Cite

Chen C et al. Skeletal muscle relaxant drug-drug-drug interactions and unintentional traumatic injury: Screening to detect three-way drug interaction signals. Br J Clin Pharmacol2022;88(11):4773-4783. doi:10.1111/bcp.15395

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.